Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -34.8% | -2.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | +1.7% | +5.1% (5yr)2 analysts |
Analysis
Recent growth has been strongest in EBIT at +1.7% over three years. Forward estimates point to EBIT at +5.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $719.27M | $5.15 | Not rated | -8.2 | +42.28% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $569.51M | $1.65 | Not rated | -2.7 | -44.77% |
Sight Sciences, Inc. NASDAQ:SGHT | $485.88M | $8.93 | Not rated | -7.5 | +55.41% |
Canopy Growth Corporation NASDAQ:CGC | $397.46M | $0.94 | Not rated | -1.8 | -52.24% |
Editas Medicine, Inc. NASDAQ:EDIT | $395.93M | $2.58 | Not rated | -2.4 | -29.76% |
Cabaletta Bio, Inc. NASDAQ:CABA | $337.52M | $2.07 | Not rated | -1.8 | -52.90% |
BioAge Labs, Inc. NASDAQ:BIOA | $265.43M | $7.05 | Not rated | -9.7 | -42.11% |
High Tide Inc. NASDAQ:HITI | $245.16M | $2.79 | Undervalued | -6.6 | -12.55% |
CVRx, Inc. NASDAQ:CVRX | $71.65M | $2.70 | Not rated | -2.5 | -71.26% |
Outset Medical, Inc. NASDAQ:OM | $56.54M | $3.05 | Not rated | -1.2 | -33.48% |
Continue the stock analysis
Jump to another research area for this company.